SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 24.69-1.3%1:25 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (4937)3/10/1999 2:10:00 PM
From: JanyBlueEyes  Read Replies (1) of 5736
 
Cacaito

<<CCSI has no partner.>>

At the moment this is a true statement which also means CCSI gets 100% of revenues generated from sales of their device (which I hear are going extremely well). Spectrx's device has been available in Europe for some time now and if you look at their quarterly reports.....sales aren't that good. There is a reason for this.

<<No signifcant difference between devices.>>

This is an inaccurate statement. One of the main differences is the FACT that Spectrx's device CAN NOT be used once an infant begins phototherapy treatment (a therapy that all hospitals utilize in the treatment of Jaundice). The Spectrx device is not FDA cleared for it either.

<<USA market as per Sprx: $30 millions.>>

This statement is wrong. Per the news release today Spectrx claims "20 million annual bilirubin blood tests worldwide".

<<CCSI is in a tough position.>>

This statement is wrong imo.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext